EMBARC-RF, NCT01200992 / 2011-003496-11: Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer |
|
|
| Terminated | 3 | 84 | US, Canada, Europe | EN3348, Mitomycin C | Bioniche Life Sciences Inc. | Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium | 04/13 | 12/13 | | |
NCT01284205: First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC |
|
|
| Withdrawn | 3 | 0 | US | Mycobacterial Cell-Wall DNA Complex, Bacillus Calmette-Guerin | Bioniche Life Sciences Inc. | Bladder Cancer | 02/14 | 02/17 | | |
NCT00406068: Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer |
|
|
| Completed | 2/3 | 129 | US, Canada | Mycobacterial cell wall-DNA complex, MCC - Urocidin | Bioniche Life Sciences Inc. | Bladder Neoplasms | 07/11 | 07/11 | | |
